The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Open accessPreprint — published as 10.1038/s41586-020-2639-4 · Paper page
Abstract
In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The incidence of grade 3 fever of BNT162b1 varied significantly in the same 30 μg group in adults aged 18–55 years, with none (0%) of 12 in the USA,17 one (8%) of 12 in Germany,18 and four (17%) of 24 in China,16 suggesting varying tolerability in different populations.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To enable the comparison of vaccine-induced S1-and RBD-binding IgG responses to previously reported data on the BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GMTs in subgroups of the donors were as follows: symptomatic infections, 90 (n = 35); asymptomatic infections, 156 (n = 3); hospitalized, 618 (n = 1).”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, several studies17, 18, 19 have reported more frequent and severe solicited systemic adverse events following the second vaccination than we found.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies17, 18, 19 showed that solicited systemic adverse events were more frequent and more severe at higher doses”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with recent reports of mRNA-LNP vaccines against the SARS-CoV-2 virus responsible for the COVID-19 pandemic which had similar rates of reactogenicity and in which reactogenicity noticeably increased after a second dose [17], [18].”
From Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The S glycoprotein mediates host cell attachment and is required for viral entry3; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.4-7”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those studies showed that solicited systemic adverse events tended to be more frequent and more severe with higher doses and after the second vaccination.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To enable the comparison of vaccine-induced serum neutralizing titres to those previously reported for BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This descriptive safety profile is similar to that described in a report of two trials of avian influenza mRNA vaccines (influenza A/H10N8 and influenza A/H7N9) that were manufactured by Moderna with the use of an earlier lipid nanoparticle capsule formulation11 and is consistent with an interim report of a phase 1–2 evaluation of a Covid-19 mRNA vaccine encoding the S receptor-binding domain.6”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the use of high doses of mRNA formulated with lipid nanoparticles (LNPs) resulted in some side effects in the candidates mRNA-1273 and BNT162b1.3,4”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [4]
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [152]
In the citing paper
“an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [1]
In the citing paper
“However, the vaccine developers eventually decide to proceed with BNT162b2 to phase II/III international clinical trials in view of its milder reactogenicity.277,278,378”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“BioNTech and Pfizer collaborated to develop five COVID-19 mRNA vaccine candidates at the beginning of the pandemic, which were based on nucleoside-modified mRNA (BNT162b2, BNT162b1, BNT162b3), non-modified mRNA (BNT162a1) and self-amplifying mRNA (BNT162c2).”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“Clinical trial data indicated that both mRNA vaccine candidates induced neutralizing antibodies at a comparable level.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“Till now, all of these candidates have entered clinical trials (Table 5).130,376,377”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“8–50-fold higher anti-RBD IgG”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“1.9–4.6-fold higher neutralization titres than convalescent serum27,123”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“In phase I trials of the two candidates, two 30 μg doses delivered 21 days apart induced high antibody and neutralizing titres and a robust CD4+ and CD8+ response with mild to moderate adverse events27,28,123,124.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“with up to 75% showing moderate fever after a 30 μg boost vaccine [82].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Both local and systemic AE occurred dose-dependently, were mostly mild to moderate and more common after boost vaccination.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“events also peaked at day 2 after dosing and were resolved by day 7.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“despite the lower mRNA-doses used, AEs were reported more frequently with BNT162b1 as compared to mRNA-1273”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Based on the reactogenicity to the 100 μg dose, no boost vaccination was performed at this dosage.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“fever was already reported after the first vaccination for all dose groups (8% for the 10 and 30 μg doses, 50% for the 100 μg dose)”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Results of a phase 1/2 dose-escalation study (mRNA doses of 10–30-100 μg) revealed similar tolerability and safety.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationCoronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,004
Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies
Zhou, T., Su, T. T., Mudianto, T., & Wang, J. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200674 · Cited by 74
Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 71
Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105370 · Cited by 73
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 66
Castaldo, M., Waliszewska‐Prosół, M., Koutsokera, M., Robotti, M., Straburzyński, M., Apostolakopoulou, L., Capizzi, M., Çibuku, O., Ambat, F. D. F., Frattale, I., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01400-4 · Cited by 72
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
Sui, Y., Li, J., Zhang, R., Prabhu, S. K., Andersen, H., Venzon, D. J., Cook, A., Brown, R., Teow, E., Velasco, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148494 · Cited by 69
Genetic Basis of Type IV Collagen Disorders of the Kidney
Quinlan, C., & Rheault, M. N. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.19171220 · Cited by 75
McMurry, R., Lenehan, P. J., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A., Anand, P., Agarwal, V., O’Horo, J. C., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.006 · Cited by 65
Ahn, J. Y., Lee, J., Suh, Y. S., Song, Y. G., Choi, Y.-J., Lee, K. H., Seo, S. H., Song, M., Oh, J., Kim, M., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00358-x · Cited by 67
An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11010130 · Cited by 66
Seo, S. H., & Jang, Y. (2020) · Vaccines · doi:10.3390/vaccines8040584 · Cited by 66
Perspectives on RNA Vaccine Candidates for COVID-19
Borah, P., Deb, P. K., Al‐Shar’i, N. A., Dahabiyeh, L. A., Venugopala, K. N., Singh, V., Shinu, P., Hussain, S., Deka, S., Chandrasekaran, B., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635245 · Cited by 67
Pu, J., Yu, Q., Yin, Z., Zhang, Y., Li, X., Li, D., Chen, H., Long, R., Zhao, Z., Mou, T., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.006 · Cited by 65
Trimpert, J., Dietert, K., Firsching, T. C., Ebert, N., Thao, T. T. N., Vladimirova, D., Kaufer, S., Labroussaa, F., Abdelgawad, A., Conradie, A. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109493 · Cited by 64
Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2
Valiente, P. A., Wen, H., Nim, S., Lee, J., Kim, H. J., Kim, J., Perez‐Riba, A., Paudel, Y. P., Hwang, I., Kim, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00655 · Cited by 65
Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O. E., Mahesh, K. C., Chaiwatpongsakorn, S., Zani, A., Kenney, A. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026153118 · Cited by 66
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65
Appelberg, S., John, L., Pardi, N., Végvári, Á., Bereczky, S., Ahlén, G., Monteil, V., Abdurahman, S., Mikaeloff, F., Beattie, M., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01568-21 · Cited by 68
Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-AnalysisPreprint
Yuan, P., Ai, P., Liu, Y., Ai, Z., Wang, Y., Cao, W., Xia, X., & Zheng, J. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3746259 · Cited by 69
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
Gundlapalli, A. V., Salerno, R. M., Brooks, J. T., Averhoff, F. M., Petersen, L. R., McDonald, L. C., Iademarco, M. F., Response, C. C.-1., Carroll, Y. I., Gorwitz, R. J., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa555 · Cited by 63
Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00590-x · Cited by 61
Zhuang, C., Lin, Z.-J., Bi, Z., Qiu, L., Hu, F.-F., Liu, X., Lin, B., Su, Y., Pan, H., Zhang, T., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1891002 · Cited by 66
Cari, L., Fiore, P., Alhosseini, M. N., Sava, G., & Nocentini, G. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102685 · Cited by 64
Duarte, L. F., Gálvez, N. M. S., Iturriaga, C., Melo-González, F., Soto, J. A., Schultz, B. M., Urzua, M. D., González, L. A., Vázquez, Y., Ríos, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742914 · Cited by 61
Saied, E. M., El‐Maradny, Y. A., Osman, A. A., Darwish, A. M. G., Nahas, H. H. A., Niedbała, G., Piekutowska, M., Abdel-Rahman, M. A., Balbool, B. A., & Abdel-Azeem, A. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111759 · Cited by 62
Sridhar, S., Joaquin, A., Bonaparte, M. I., Bueso, A., Chabanon, A.-L., Chen, A., Chicz, R. M., Diemert, D. J., Essink, B. J., Fu, B., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00764-7 · Cited by 60
Self-citationShepherd, B. L. O., Scott, P. T., Hutter, J. N., Lee, C., McCauley, M., Guzman, I., Bryant, C., McGuire, S., Kennedy, J. K., Chen, W.-H., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00410-x · Cited by 63
Li, D.-P., Edwards, R., Manne, K., Martinez, D. R., Schäfer, A., Alam, S., Wiehe, K., Lu, X.-Z., Parks, R., Sutherland, L. L., et al. (2021) · bioRxiv · doi:10.1101/2020.12.31.424729 · Cited by 62
Linares-Fernández, S., Moreno, J., Lambert, E., Mercier-Gouy, P., Vachez, L., Verrier, B., & Exposito, J.-Y. (2021) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2021.10.007 · Cited by 62
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
Ashraf, M. U., Kim, Y., Kumar, S., Seo, D., Ashraf, M., & Bae, Y. (2021) · Vaccines · doi:10.3390/vaccines9020171 · Cited by 62
Pan, H., Liu, J., Huang, B., Li, G., Chang, X., Liu, Y., Wang, W., Chu, K., Hu, J., Li, J., et al. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001573 · Cited by 59
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
Sui, Y., Bekele, Y., & Berzofsky, J. A. (2021) · Pathogens · doi:10.3390/pathogens10020138 · Cited by 57
Instrumental analysis of RNA modifications
Yoluç, Y., Ammann, G., Barraud, P., Jora, M., Limbach, P. A., Motorin, Y., Marchand, V., Tisné, C., Borland, K. M., & Kellner, S. M. (2021) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2021.1887807 · Cited by 59
Reasons for success and lessons learnt from nanoscale vaccines against COVID-19
Kisby, T., Yılmazer, A., & Kostarelos, K. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00946-9 · Cited by 62
SARS-CoV-2: Targeted managements and vaccine development
Bakhiet, M., & Taurin, S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.11.001 · Cited by 65
SARS-CoV-2: vaccines in the pandemic era
Li, D., & Li, Q. (2021) · Military Medical Research · doi:10.1186/s40779-020-00296-y · Cited by 61
Valdés-Balbín, Y., Santana-Mederos, D., Paquet, F., Fernández-Castillo, S., Climent, Y., Chiodo, F., Rodríguez, L., Ramírez, B. S., León, K., Hernández, T., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00216 · Cited by 53
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
Majdoubi, A., Michalski, C., O’Connell, S. E., Dada, S., Narpala, S., Gelinas, J. P., Mehta, D., Cheung, C., Winkler, D. F. H., Basappa, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146316 · Cited by 57
Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia
Alamer, E., Alhazmi, A., Qasir, N. A., Alamer, R. A., Areeshi, H., Gohal, G. A., Qadri, M. M., Hashem, A. M., & Algaissi, A. A. (2021) · Vaccines · doi:10.3390/vaccines9111297 · Cited by 57
Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
Li, C., Callahan, A. J., Simon, M. D., Totaro, K. A., Mijalis, A. J., Phadke, K.-S., Zhang, G., Hartrampf, N., Schissel, C. K., Zhou, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24598-4 · Cited by 57
Is there a role for childhood vaccination against COVID‐19?
Eberhardt, C. S., & Siegrist, C. (2020) · Pediatric Allergy and Immunology · doi:10.1111/pai.13401 · Cited by 58
Bleicher, I., Kadour‐Peero, E., Sagi‐Dain, L., & Sagi, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.09.043 · Cited by 55
Korzun, T., Moses, A. S., Jozić, A., Grigoriev, V., Newton, S., Kim, J., Diba, P., Sattler, A. L., Levasseur, P. R., Le, N., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05088 · Cited by 64
van Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100352 · Cited by 56
Precision therapeutic targets for COVID-19
Krumm, Z. A., Lloyd, G. M., Francis, C. P., Nasif, L. H., Mitchell, D. A., Golde, T. E., Giasson, B. I., & Xia, Y. (2021) · Virology Journal · doi:10.1186/s12985-021-01526-y · Cited by 58
Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration
AboulFotouh, K., Cui, Z., & Williams, R. O. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-01974-3 · Cited by 56
Bajad, N. G., Swetha, R., Gutti, G., Sharma, A., Singh, M., Kumar, A., & Singh, S. K. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100026 · Cited by 58
Kim, H., & Shin, S. J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.891878 · Cited by 60
Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies
Yu, L., Liu, S., Jia, S., & Xu, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115049 · Cited by 59
The evolutionary dynamics of endemic human coronaviruses
Jo, W. K., Drosten, C., & Drexler, J. F. (2021) · Virus Evolution · doi:10.1093/ve/veab020 · Cited by 60
Bakadia, B. M., He, F., Souho, T., Lamboni, L., Ullah, M. W., Boni, B. O. O., Ahmed, A. A. Q., Mukole, B. M., & Yang, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111008 · Cited by 56
Innate and adaptive immune responses toward nanomedicines
Viana, I. M. D. O., Roussel, S., Defrêne, J., Lima, E. M., Barabé, F., & Bertrand, N. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.022 · Cited by 57
Ripabelli, G., Tamburro, M., Buccieri, N., Adesso, C., Caggiano, V., Cannizzaro, F., Palma, M. A. D., Mantuano, G., Montemitro, V. G., Natale, A., et al. (2021) · Journal of Community Health · doi:10.1007/s10900-021-01039-3 · Cited by 58
Korosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Gholami, S., Ghaemi, M. S., Moyles, I. R., Craig, M., Ooi, H. K., & Heffernan, J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-25134-0 · Cited by 59
Sing, C., Tang, C. T.-L., Chui, C. S. L., Fan, M., Lai, F. T. T., Li, X., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., Hung, I. F., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26478 · Cited by 56
Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 58
Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
Malladi, S. K., Singh, R., Pandey, S., Gayathri, S., Kanjo, K., Ahmed, S., Khan, M. S. A. A., Kalita, P., Girish, N., Upadhyaya, A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016284 · Cited by 52
Lombardi, A., Bozzi, G., Ungaro, R., Villa, S., Castelli, V., Mangioni, D., Muscatello, A., Gori, A., & Bandera, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657711 · Cited by 51
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 51
Cari, L., Alhosseini, M. N., Fiore, P., Pierno, S., Pacor, S., Bergamo, A., Sava, G., & Nocentini, G. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102742 · Cited by 54
Murase, K. (2022) · Toxins · doi:10.3390/toxins14020078 · Cited by 52
Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review
Veronese, N., Petrović, M., Bénétos, A., Denkinger, M. D., Guðmundsson, A., Knol, W., Marking, C., Soulis, G., Maggi, S., & Cherubini, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101455 · Cited by 55
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
Carbone, M., Lednicky, J. A., Xiao, S., Venditti, M., & Bucci, E. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.014 · Cited by 62
Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report
Elboraey, M. O., & Essa, E. E. S. F. (2021) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2021.06.019 · Cited by 51
Innovations and development of Covid-19 vaccines: A patent review
Alshrari, A. S., Hudu, S. A., Imran, M., Asdaq, S. M. B., Alreshidi, M. A., & Rabbani, S. I. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.021 · Cited by 54
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Microemulsion Based Nanostructures for Drug Delivery
Arredondo-Ochoa, T., & Silva-Martínez, G. A. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.753947 · Cited by 55
Protective neutralizing epitopes in SARS‐CoV‐2
Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 49
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
Mandolesi, M., Sheward, D. J., Hanke, L., Ma, J., Pushparaj, P., Vidakovics, L. P., Kim, C., Ádori, M., Lenart, K., Loré, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100252 · Cited by 46
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Current Vaccine Platforms in Enhancing T-Cell Response
Ura, T., Takeuchi, M., Kawagoe, T., Mizuki, N., Okuda, K., & Shimada, M. (2022) · Vaccines · doi:10.3390/vaccines10081367 · Cited by 56
Rawson, J. M. O., Duchon, A. A., Nikolaitchik, O. A., Pathak, V. K., & Hu, W.-S. (2021) · Viruses · doi:10.3390/v13020173 · Cited by 51
Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance
Nagy, N. A., de Haas, A. M., Geijtenbeek, T. B. H., van Ree, R., Tas, S. W., van Kooyk, Y., & de Jong, E. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674048 · Cited by 49
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45
Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning
Luo, J., Molbay, M., Chen, Y., Horvath, I., Kadletz, K., Kick, B., Zhao, S., Al-Maskari, R., Singh, I., Ali, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02528-1 · Cited by 53
Chourasia, R., Padhi, S., Phukon, L. C., Abedin, M. M., Singh, S. P., & Rai, A. K. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.601753 · Cited by 49
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Aliahmad, P., Miyake-Stoner, S. J., Geall, A. J., & Wang, N. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00435-8 · Cited by 50
Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?
Cosentino, M., & Marino, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810881 · Cited by 56
Liu, G., Carter, B., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.010 · Cited by 48
The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
Won, J., & Lee, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249775 · Cited by 49
Ameratunga, R., Longhurst, H. J., Steele, R. H., Lehnert, K., Leung, E. Y., Brooks, A. E. S., & Woon, S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.019 · Cited by 49
Liao, Y., Li, Y., Pei, R., Fang, X. D., Zeng, P., Fan, R., Ou, Z., Deng, J., Zhou, J., Guan, W., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1951126 · Cited by 47
Valcarce, V., Stafford, L. S., Neu, J., Cacho, N. T., Parker, L. A., Mueller, M., Burchfield, D. J., Li, N., & Larkin, J. (2021) · Breastfeeding Medicine · doi:10.1089/bfm.2021.0122 · Cited by 48
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
Lozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamı́, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 50
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 49
Naqvi, S., Saleem, S., Naqvi, F., Billah, S. M., Nielsen, E., Fogleman, E., Peres‐da‐Silva, N., Figueroa, L., Mazariegos, M., Garces, A. L., et al. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17226 · Cited by 49
Kurhade, C., Zou, J., Xia, H., Liu, M., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Şahin, U., Jansen, K. U., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2099305 · Cited by 46
Self-citationDahlgren, M. W., Plumb, A. W., Niss, K., Lahl, K., Brunak, S., & Johansson‐Lindbom, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932388 · Cited by 48
Hwang, Y., Shepherd, S. J., Kim, D., Mukalel, A. J., Mitchell, M. J., Issadore, D. A., & Lee, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c12965 · Cited by 50
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · doi:10.1101/2020.12.23.424138 · Cited by 48
A Focus on “Bio” in Bio–Nanoscience: The Impact of Biological Factors on Nanomaterial Interactions
Cortez‐Jugo, C., Czuba‐Wojnilowicz, E., Tan, A. E. Q., & Caruso, F. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100574 · Cited by 46
Intapiboon, P., Seepathomnarong, P., Ongarj, J., Surasombatpattana, S., Uppanisakorn, S., Mahasirimongkol, S., Sawaengdee, W., Phumiamorn, S., Sapsutthipas, S., Sangsupawanich, P., et al. (2021) · Vaccines · doi:10.3390/vaccines9121375 · Cited by 48
Dube, T., Ghosh, A., Mishra, J., Kompella, U. B., & Panda, J. J. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000172 · Cited by 52
Prompetchara, E., Ketloy, C., Tharakhet, K., Kaewpang, P., Buranapraditkun, S., Techawiwattanaboon, T., Sathean-anan-kun, S., Pitakpolrat, P., Watcharaplueksadee, S., Phumiamorn, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248007 · Cited by 47
Transcription, mRNA Export, and Immune Evasion Shape the Codon Usage of Viruses
Mordstein, C., Cano, L., Castillo-Morales, A., Young, B., Ho, A. T., Rice, A. M., Liss, M. A., Hurst, L. D., & Kudla, G. (2021) · Genome Biology and Evolution · doi:10.1093/gbe/evab106 · Cited by 48
Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
Hong, J., Kwon, H. J., Cachau, R., Chen, C. Z., Butay, K. J., Duan, Z., Li, D., Ren, H., Liang, T., Zhu, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201433119 · Cited by 47
Metadata
- Authors
- Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ӧ., Tompkins, K. R., Walsh, E. E., Frenck, R., Falsey, A. R., Dormitzer, P. R., Gruber, W. C., Şahin, U., & Jansen, K. U.
- Affiliations
- NYU Langone Health (US)
- University of Maryland, Baltimore (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (United States) (US)
- The University of Texas Medical Branch at Galveston (US)
- Rochester General Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- BioNTech (Germany) (DE)
- Corresponding author
- Absalon, Judith
- ORCID
- Mulligan, Mark J.
- Lyke, Kirsten E.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Neuzil, Kathleen
- Raabe, Vanessa
- Swanson, Kena A.
- Li, Ping
- Cooper, David
- Fontes-Garfias, Camila
- Shi, Pei-Yong
- Tompkins, Kristin R.
- Walsh, Edward E.
- Frenck, Robert
- Falsey, Ann R.
- Dormitzer, Philip R.
- Gruber, William C.
- Şahin, Uğur
- Jansen, Kathrin U.
- Venue
- Nature
- Publisher
- openRxiv
- Published
- 2020-07-01
- Volume
- 586
- Issue
- 7830
- Pages
- 589-593
- ISSN
- 0028-0836 (ISSN-L)
- OpenAlex
- W3048620154
- Cited by
- 1,569
- References
- 24
- Citations by year
- 2026: 47 · 2025: 92 · 2024: 111 · 2023: 183 · 2022: 355 · 2021: 623 · 2020: 152
- FWCI
- 43.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Pfizer
- Cincinnati Children's Hospital Medical Center
- University of Rochester
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001445)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, dose escalation, vaccine safety, vaccine immunogenicity, neutralizing antibodies, reactogenicity, healthy adults
- MeSH terms
- COVID-19, COVID-19 Vaccines, COVID-19 Serotherapy, Adult, Antibodies, Viral, Female, Humans, Immunoglobulin G, Immunization, Passive, Male, Middle Aged, Pneumonia, Viral, Time Factors, Viral Vaccines, Coronavirus Infections, Young Adult, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
